<div id="readability-page-1"><p>Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15, Zacks reports.</p><div><p><span></span><span>Get <strong>Prelude Therapeutics</strong> alerts:</span></p></div><h2>Prelude Therapeutics Stock Up 2.6%</h2><ul><li>Analysts are Upgrading These 3 Stocks…Here’s Why</li></ul><p>NASDAQ:PRLD traded up $0.04 on Wednesday, reaching $1.39. The company's stock had a trading volume of 231,680 shares, compared to its average volume of 511,617. The firm has a market cap of $78.39 million, a price-to-earnings ratio of -0.85 and a beta of 1.37. The stock has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.08. Prelude Therapeutics has a 12-month low of $0.61 and a 12-month high of $4.22. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in  Prelude Therapeutics by 170.7% during the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company's stock valued at $26,000 after purchasing an additional 21,330 shares in the last quarter.  Marshall Wace LLP bought a new stake in shares of  Prelude Therapeutics during the second quarter valued at approximately $34,000.  XTX Topco Ltd grew its position in  Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company's stock valued at $34,000 after buying an additional 17,873 shares in the last quarter.  Shay Capital LLC bought a new position in  Prelude Therapeutics during the second quarter valued at about $61,000.  Finally, Jane Street Group LLC acquired a new position in shares of  Prelude Therapeutics in the 2nd quarter worth $74,000. Hedge funds and other institutional investors own  79.72% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>PRLD has been the subject of a number of recent analyst reports. HC Wainwright  reiterated a &#34;buy&#34; rating and set a $5.00 price target on shares of Prelude Therapeutics in a report on Tuesday, September 23rd. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Prelude Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Prelude Therapeutics to a &#34;hold&#34; rating in a research note on Saturday, October 18th. Finally, JMP Securities reduced their target price on Prelude Therapeutics from $4.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research note on Monday, August 18th. Two research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $4.00.</p><p><b>Get Our Latest Research Report on PRLD</b></p><h2>Prelude Therapeutics Company Profile</h2> (Get Free Report)<p>Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Prelude Therapeutics</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay</li><li>3 Best Fintech Stocks for a Portfolio Boost</li><li>Occidental Petroleum is a Buy in Q4 2025</li><li>What is the MACD Indicator and How to Use it in Your Trading</li><li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJMRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Prelude Therapeutics Right Now?</h2><p>Before you consider Prelude Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.</p><p>While Prelude Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRLD

<p>Prelude Therapeutics reported quarterly earnings of ($0.26) per share, beating the consensus estimate of ($0.41). The stock rose 2.6% to $1.39. Analysts have mixed ratings, with a consensus "Hold" and a target price of $4.00. Institutional investors own 79.72% of the stock. The company is developing several cancer treatments in clinical trials.</p>

Prelude Therapeutics (NASDAQ:PRLD) Issues Earnings Results